BofA Upgrades Gilead Sciences, Says Stock Undervalued Given HIV Franchise Strength and Pipeline Upside

Gilead Sciences stock looks underappreciated and oversold, according to BofA analysts
BofA upgraded Gilead stock to Buy from Neutral and raised its price target
Analysts see upside from Gilead's HIV franchise and pipeline
Gilead generates strong cash flow but trades at a discount to peers
BofA argues Gilead's valuation does not fully reflect its remdesivir sales and earnings power

barrons.com

Relevant topic timeline:

8/25/2023

BofA sees "trouble" ahead for tech stocks despite big inflows

Strategists at BofA Global Research predict trouble for technology stocks in the second half of the year despite the sector's recent large inflows, pointing to the correlation between central bank liquidity and the Nasdaq Composite, which has outperformed by 28% this year, as evidence.